Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease.

aspirin hypersensitivity cluster analysis inflammatory phenotypes non-eosinophilic asthma

Journal

Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043

Informations de publication

Date de publication:
Mar 2023
Historique:
revised: 12 02 2023
received: 06 12 2022
accepted: 24 02 2023
medline: 29 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: ppublish

Résumé

The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD

Sections du résumé

BACKGROUND BACKGROUND
The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management.
METHODS METHODS
Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients.
RESULTS RESULTS
The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D
CONCLUSIONS CONCLUSIONS
Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD

Identifiants

pubmed: 36973957
doi: 10.1002/clt2.12235
pmc: PMC10009799
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12235

Subventions

Organisme : Narodowe Centrum Nauki
ID : UMO-2015/19/B/NZ5/00096
Organisme : Narodowe Centrum Nauki
ID : UMO-2018/31/B/NZ5/0080

Informations de copyright

© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Références

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1686-9
pubmed: 22264478
Blood. 2012 Apr 19;119(16):3790-8
pubmed: 22262771
Am J Respir Crit Care Med. 2015 Sep 15;192(6):682-94
pubmed: 26067893
Allergy Asthma Proc. 2021 Nov 1;42(6):530-536
pubmed: 34871161
Clin Exp Allergy. 2015 Dec;45(12):1779-89
pubmed: 26449970
Clin Exp Allergy. 2021 Aug;51(8):1046-1056
pubmed: 33905579
Can Respir J. 2011 May-Jun;18(3):144-8
pubmed: 21766077
Respir Med. 2019 Jun;152:51-59
pubmed: 31128610
N Engl J Med. 2017 Sep 7;377(10):936-946
pubmed: 28877011
Eur Respir J. 2021 Feb 4;57(2):
pubmed: 33008937
J Allergy Clin Immunol. 2013 Oct;132(4):856-65.e1-3
pubmed: 23806637
J Allergy Clin Immunol. 2021 Feb;147(2):587-599
pubmed: 32540397
J Allergy Clin Immunol. 2017 Jul;140(1):101-108.e3
pubmed: 28279492
Allergy. 2020 Jul;75(7):1649-1658
pubmed: 32012310
N Engl J Med. 2018 Sep 13;379(11):1060-1070
pubmed: 30207919
Allergy. 2020 Apr;75(4):831-840
pubmed: 31803947
J Allergy Clin Immunol. 2016 Mar;137(3):833-43
pubmed: 26792210
J Allergy Clin Immunol. 2021 Aug;148(2):439-449.e5
pubmed: 33819512
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
Allergy. 2019 May;74(5):922-932
pubmed: 30446997
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Allergy. 2020 Feb;75(2):311-325
pubmed: 31309578
Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95
pubmed: 19483109
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-1141
pubmed: 33065369
J Allergy Clin Immunol. 2022 Apr;149(4):1286-1295
pubmed: 34543652
Am J Respir Crit Care Med. 2012 Mar 15;185(6):612-9
pubmed: 22268133
Allergy. 2021 Jan;76(1):114-130
pubmed: 32279330
Allergy. 2017 Apr;72(4):616-626
pubmed: 27805264
J Allergy Clin Immunol. 2021 Apr;147(4):1318-1328.e5
pubmed: 33189729
J Allergy Clin Immunol. 2021 Feb;147(2):501-503
pubmed: 33358894
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2344-2355
pubmed: 33482419
Allergy. 2019 Sep;74(9):1649-1659
pubmed: 30865306
J Asthma Allergy. 2018 Oct 29;11:267-281
pubmed: 30464537
Allergy. 2021 Jan;76(1):14-44
pubmed: 32484954
BMC Pulm Med. 2016 Apr 05;16:46
pubmed: 27044366
Eur Respir J Suppl. 2002 Sep;37:1s-2s
pubmed: 12361359
Allergy. 2020 Mar;75(3):713-716
pubmed: 31583712

Auteurs

Lucyna Mastalerz (L)

2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

Natalia Celejewska-Wójcik (N)

2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

Adam Ćmiel (A)

Department of Applied Mathematics, AGH University of Science and Technology, Krakow, Poland.

Krzysztof Wójcik (K)

2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

Joanna Szaleniec (J)

Department of Otolaryngology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.

Karolina Hydzik-Sobocińska (K)

Department of Otolaryngology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.

Jerzy Tomik (J)

Department of Otolaryngology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.

Marek Sanak (M)

2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

Classifications MeSH